-
Scandic Trust Group strengthens sales network with First Idea Consultant
-
Fleetwood and Lowry lift each other into Abu Dhabi lead
-
Fleetwod and Lowry lift each other into Abu Dhabi lead
-
New Zealand make changes after Barrett brothers' injuries as Scotland drop Van der Merwe
-
Dallas Cowboys' Marshawn Kneeland dies at 24: franchise
-
Pegula dispatches Paolini to keep WTA Finals semis bid alive
-
Dutch giants Ajax sack coach John Heitinga
-
Kirchner on trial in Argentina's 'biggest ever' corruption case
-
Amorim urges Man Utd to 'focus on future' after Ronaldo criticism
-
US judge drops criminal charges against Boeing over 737 MAX 8 crashes
-
World must face 'moral failure' of missing 1.5C: UN chief to COP30
-
UK grandmother leaves Indonesia death row to return home
-
Garcia broken nose adds to Barca defensive worries
-
Tight UK security ahead of match against Israeli club
-
Ethiopia's Afar region says attacked by Tigray forces
-
Nancy Pelosi, Democratic giant, Trump foe, first woman House speaker, to retire
-
Israel strikes Hezbollah targets in Lebanon
-
Burger strikes as South Africa restrict Pakistan to 269-9 in second ODI
-
Stocks slip as investors weigh earnings, tariffs
-
Police say 19 held after raid at Swedish start-up Stegra to be deported
-
Kante returns as France seek to clinch World Cup berth
-
Marcus Smith starts at full-back as England ring changes for Fiji
-
Kolisi 100th Test 'no distraction' for Erasmus' South Africa
-
Teetering Belgian government given more time to agree budget
-
Merz backs EU plan to protect steel sector from Chinese imports
-
New Zealand make Scotland changes after Barrett brothers' injuries
-
'Roy of the Rovers story' -- Farrell handed Ireland debut for Japan Test
-
Stones backs Man City team-mate Foden to pose England dilemma for Tuchel
-
Djokovic to face Alcaraz in ATP Finals groups
-
Facing climate 'overshoot', world heads into risky territory
-
Springbok skipper Kolisi to play 100th Test against France
-
Typhoon Kalmaegi hits Vietnam after killing 140 in Philippines
-
Bank of England leaves rate unchanged before UK budget
-
Germany recall Sane, hand El Mala debut for World Cup qualifers
-
India thump Australia to take 2-1 lead in T20 series
-
Cameroon's Biya, world's oldest president, sworn in for 8th term
-
Flick holding firm on Barca high line despite defensive woes
-
Battered US businesses eye improved China trade at Shanghai expo
-
France opt for Le Garrec as Dupont replacement for 'best team ever' South Africa
-
Drugmaker AstraZeneca profit jumps as US business grows
-
'Vibe coding' named word of the year by Collins dictionary
-
Vietnam evacuates thousands from coast ahead of Typhoon Kalmaegi
-
European stocks fall after gains in Asia, US
-
MotoGP legend Agostini admires Marc Marquez's 'desire to win'
-
Nepal searches for avalanche victims
-
Hezbollah rejects any negotiations between Lebanon and Israel
-
Chapman blitz leads Black Caps to tight T20 victory over West Indies
-
France urges EU to sanction Shein platform
-
France opt for Le Garrec as Dupont replacement for South Africa Test
-
Turmoil in tiaras at Miss Universe pageant in Thailand
Moderna Covid vaccine gets full US approval
The US Food and Drug Administration (FDA) announced Monday that it has granted full approval to Moderna's Covid-19 "Spikevax" vaccine, which had previously received an emergency use authorization in the United States.
"The public can be assured that Spikevax meets the FDA's high standards for safety, effectiveness and manufacturing quality required of any vaccine approved for use in the United States," acting FDA commissioner Janet Woodcock said in a statement.
"The FDA's approval of Spikevax is a significant step in the fight against the Covid-19 pandemic, marking the second vaccine approved to prevent Covid-19," Woodcock said.
The full approval of the Moderna vaccine is for individuals aged 18 or older.
A Pfizer vaccine for individuals aged 16 or older received full FDA approval at the end of August.
Woodcock said she hoped FDA approval of the Moderna vaccine "may instill additional confidence in making the decision to get vaccinated."
Moderna CEO Stephane Bancel called the FDA move a "momentous milestone" for the company.
"Our Covid-19 vaccine has been administered to hundreds of millions of people around the world, protecting people from Covid-19 infection, hospitalization and death," Bancel said in a statement.
The Moderna vaccine received an emergency use authorization in December 2020.
The full approval from the FDA concerns the first two doses of the Moderna vaccine. A booster dose remains under an emergency use authorization.
The FDA said clinical trials to determine the effectiveness of Spikevax included 14,287 vaccine recipients and 14,164 placebo recipients.
The most common side effects by clinical trial participants were pain at the injection site, fatigue, headaches, muscle or joint pain, chills, nausea or vomiting and swollen lymph nodes, the FDA said.
It said there was an increased risk in men aged 18 to 24 of myocarditis -- inflammation of the heart muscle -- and pericarditis -- inflammation of tissue surrounding the heart -- following vaccination with the second dose.
But, the FDA said, it has determined that the "benefits of the vaccine outweigh the risk of myocarditis and pericarditis in individuals 18 years of age and older."
S.F.Warren--AMWN